We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current BPMC market cap is 5.98B. The company's latest EPS is USD -7.9808 and P/E is -11.80.
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 56.57M | 71.96M | 96.12M | 138.16M | 128.19M |
Operating Income | -128.98M | -105.11M | -78.82M | -43.05M | -48.01M |
Net Income | -133.71M | -110.92M | 89.14M | -50M | -56.27M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 66.51M | 793.74M | 180.08M | 204.04M | 249.38M |
Operating Income | -361.33M | 308.71M | -641.98M | -537.52M | -486.28M |
Net Income | -347.69M | 313.88M | -644.09M | -557.52M | -506.98M |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 1.11B | 1.05B | 1.04B | 1.2B | 1.2B |
Total Liabilities | 902.69M | 918.64M | 727.79M | 883.32M | 886.5M |
Total Equity | 202.61M | 130.61M | 310.69M | 320.24M | 313.15M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 707.69M | 1.72B | 1.25B | 1.35B | 1.05B |
Total Liabilities | 243.34M | 248.31M | 281.49M | 835.23M | 918.64M |
Total Equity | 464.36M | 1.47B | 970.74M | 514.68M | 130.61M |
Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -357.92M | -436.85M | -101.51M | -149.59M | -163.22M |
Investing | 195.27M | 274.04M | 77.13M | -111.16M | -81.21M |
Financing | 103.7M | 119.23M | 66.96M | 244.98M | 263.35M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -278.02M | 387.04M | -298.65M | -502.28M | -436.85M |
Investing | -16.47M | -434.25M | -225.86M | -149.54M | 274.04M |
Financing | 340.64M | 617.76M | 50.72M | 561.81M | 119.23M |
Market Cap | 5.98B |
Price to Earnings Ratio | -11.80 |
Price to Sales Ratio | 23.98 |
Price to Cash Ratio | 83.9 |
Price to Book Ratio | 45.79 |
Dividend Yield | - |
Shares Outstanding | 63.53M |
Average Volume (1 week) | 736.23k |
Average Volume (1 Month) | 741.53k |
52 Week Change | 40.52% |
52 Week High | 121.90 |
52 Week Low | 65.68 |
Spread (Intraday) | 3.64 (3.79%) |
Company Name | Blueprint Medicines Corporation |
Address |
1209 orange street wilmington, delaware 19801 |
Website | https://www.blueprintmedicines.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions